A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.

Medical Oncology
E KarapanagiotouKostas Syrigos

Abstract

Our study involves a preliminary phase II trial, which evaluates the activity, feasibility and tolerability of a sequential combination of docetaxel and gemcitabine followed by docetaxel and carboplatin, as first-line treatment for inoperable NSCLC. Twenty-six chemo-naïve patients aged less than 75 years with histologically or cytologically confirmed unresectable stage IIIB, IV or relapsed post-operative metastatic NSCLC were included in the study. Gemcitabine 1,250 mg/m(2) was administered and was followed by docetaxel 65 mg/m(2). Treatment was administered on days 1 and 14 in a 28-day cycle for three consecutive cycles. If patients had no progressive disease after three cycles of chemotherapy, they received another three cycles of docetaxel 65 mg/m(2) followed by carboplatin AUC5 on day 1 in a 21-day cycle. Recombinant human granocyte colony-stimulating factor (rhG-CSF) was given prophylactically. In addition, all patients received standard pre- and post- treatment with oral dexamethasone. Response rates at three cycles were: 19% achieved a partial response (PR), 46% had stable disease (SD) and 23% had progressive disease. At six cycles, 8% of the patients maintained PR, 19% showed SD and 35% had progressive disease. The medi...Continue Reading

References

Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaB Glisson
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L CrinòM Tonato
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I E SmithS Ashley
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiMerrill S Kies
Dec 7, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Robert Pirker
Jan 16, 2003·Chest·Mark A SocinskiUNKNOWN American College of Chest Physicians
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MauerE E Vokes
Jun 1, 2004·American Journal of Clinical Oncology·Javier CortesSalvador Martin-Algarra
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vassilis GeorgouliasAthanasios Alegakis
Feb 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vassilis GeorgouliasDora Chatzidaki
Mar 3, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-L PujolC Clary
Nov 1, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Manuel Cobo DolsManuel Benavides Orgaz

❮ Previous
Next ❯

Citations

Oct 5, 2010·Metal-based Drugs·Nektaria MakriliaMuhammad Wasif Saif
Jul 2, 2011·International Archives of Allergy and Immunology·Ekaterini SyrigouKostas N Syrigos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.